Dec. 11 at 2:18 PM
$CRBP $NVO bought out Inversago for 1.08B to acquire Monlunabant what was in Phase 1b/2 at that time. Monlunabant still shows significant levels of Psych AEs and GI-related AEs, wherease CRB- 913 shows nearly NONE of Psych and GI AEs (NO vomit + NO nausea), its safety profiles are so clean. At Day 14 (just 2wk), CRB-913 already shows 2.9% placebo-adjusted weight loss. If it can give 5-6% weight loss at 14 wk from P1b study (which is very likely) with the same clean safety profiles as we saw so far, CRB-913 is definitely the Best-in-Class and will be chased by some BPs for over 2B.
$PFE $MRK $LLY